LaFleur & Godfrey LLC Raises Holdings in Johnson & Johnson (NYSE:JNJ)

Share on StockTwits

LaFleur & Godfrey LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 99,519 shares of the company’s stock after acquiring an additional 1,575 shares during the period. Johnson & Johnson makes up approximately 3.5% of LaFleur & Godfrey LLC’s holdings, making the stock its 10th largest holding. LaFleur & Godfrey LLC’s holdings in Johnson & Johnson were worth $13,861,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Cubist Systematic Strategies LLC grew its position in Johnson & Johnson by 461.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 206,905 shares of the company’s stock worth $28,818,000 after acquiring an additional 170,030 shares during the last quarter. Family Management Corp grew its position in Johnson & Johnson by 14.8% during the 2nd quarter. Family Management Corp now owns 31,336 shares of the company’s stock worth $4,364,000 after acquiring an additional 4,035 shares during the last quarter. Wunderlich Capital Managemnt bought a new stake in Johnson & Johnson during the 2nd quarter worth approximately $792,000. Harfst & Associates Inc. grew its position in Johnson & Johnson by 5.8% during the 2nd quarter. Harfst & Associates Inc. now owns 4,910 shares of the company’s stock worth $683,000 after acquiring an additional 269 shares during the last quarter. Finally, Vivaldi Capital Management LLC grew its position in Johnson & Johnson by 114.3% during the 2nd quarter. Vivaldi Capital Management LLC now owns 7,766 shares of the company’s stock worth $1,082,000 after acquiring an additional 4,142 shares during the last quarter. Hedge funds and other institutional investors own 72.01% of the company’s stock.

NYSE:JNJ opened at $131.65 on Friday. The stock’s fifty day moving average price is $130.02 and its two-hundred day moving average price is $135.71. Johnson & Johnson has a 52-week low of $121.00 and a 52-week high of $148.99. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.04 and a current ratio of 1.33. The company has a market cap of $344.17 billion, a price-to-earnings ratio of 16.09, a P/E/G ratio of 2.21 and a beta of 0.68.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.42 by $0.16. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The firm had revenue of $20.56 billion for the quarter, compared to the consensus estimate of $20.39 billion. During the same quarter in the prior year, the business earned $2.10 EPS. The business’s revenue for the quarter was down 1.3% compared to the same quarter last year. On average, equities analysts predict that Johnson & Johnson will post 8.6 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 2.89%. The ex-dividend date was Monday, August 26th. Johnson & Johnson’s dividend payout ratio is 46.45%.

A number of equities research analysts recently commented on JNJ shares. Credit Suisse Group set a $156.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Goldman Sachs Group set a $169.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Bank of America restated a “hold” rating and set a $150.00 price target on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price target on the stock. in a research report on Thursday, July 18th. Finally, Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Johnson & Johnson currently has an average rating of “Buy” and an average price target of $150.60.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: What causes a stock to be most active?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Macquarie Group Ltd. Sells 270,835 Shares of Columbia Property Trust
Macquarie Group Ltd. Sells 270,835 Shares of Columbia Property Trust
Macquarie Group Ltd. Has $2.46 Million Position in Fox Factory Holding Corp
Macquarie Group Ltd. Has $2.46 Million Position in Fox Factory Holding Corp
Macquarie Group Ltd. Has $2.59 Million Stock Holdings in Ambarella Inc
Macquarie Group Ltd. Has $2.59 Million Stock Holdings in Ambarella Inc
Macquarie Group Ltd. Lowers Position in Juniper Networks, Inc.
Macquarie Group Ltd. Lowers Position in Juniper Networks, Inc.
Morgan Stanley Has $12.98 Million Stock Holdings in Harsco Co.
Morgan Stanley Has $12.98 Million Stock Holdings in Harsco Co.
Apple Hospitality REIT Inc  Stock Holdings Boosted by Macquarie Group Ltd.
Apple Hospitality REIT Inc Stock Holdings Boosted by Macquarie Group Ltd.


© 2006-2019 Ticker Report